UK: MHRA published guidance on clinical trial risk assessment, oversight and monitoring activities.
The UK Medicines & Healthcare products Regulatory Agency (MHRA) has published guidance on clinical trial risk assessments, oversight and monitoring activities in two documents.
It aims to assist sponsors and those conducting trials on implementing adequate oversight and monitoring processes for trials of investigational medical products.
Meditrial provides full-service trial management, including on-site and remote monitoring. Please feel free to contact us for advice and support with your clinical study!
MHRA recommends to perform and document a risk assessment for each proposed clinical investigation as early as possible to determine whether it falls under the Clinical Trials legislation and whether there are barriers to its execution.
The guidance states: “The risk assessment must be specific to the proposed trial and whilst the process may include templates or a guide on the areas to consider in the risk assessment, care should be taken to examine the potential risks of the proposed trial, which may present new areas that have not been considered in previous trials. This is why it is a bespoke approach.”
Moreover, Sponsors should keep the risk assessment in the trial master file and, where appropriate, inform site staff of its content. It has to be re-examined when new information becomes available, such as after an interim analysis.
The second MHRA guidance lists aspects that are important in determining the oversight and monitoring strategy, explaining that sponsors should establish processes that reflect the known risks of a trial. If an error in an activity would have a negative impact on participant safety and trial results, sponsors should make it a focus of oversight and monitoring.
The MHRA guidance moves away from the traditional approach of seeking to assess compliance with every detail of the protocol and checking every data point against source documents.
Read more on the MHRA website.
See the MHRA Guidance.
Contact Meditrial today for immediate assistance in the UK!
Table of Contents
Getting a CE mark for medical devices: a step-by-step guide
Practical guidance on the CE mark for medical devices under EU MDR, from classification and evidence to conformity assessment and EUDAMED
A Practical RBQM Framework for Medical Device Trials
Risk-based quality management for medical device trials, with practical actions for risk assessment, monitoring, data review, and trial oversight
EU Breakthrough Medical Devices Under MDCG 2025-9 (BtX)
EU breakthrough medical devices gain a clearer regulatory pathway under MDCG 2025-9, with early advice and lifecycle evidence planning
What Swissmedic Fast-Track Means for Clinical Trial Sponsors
Swissmedic swissethics Fast-Track Pilot Project accelerates eligible trial reviews and makes coordinated regulatory preparation increasingly important.
FDA Breakthrough Device Acceleration
How innovative MedTech companies can accelerate FDA approval, secure Medicare coverage, and reach patients faster—starting with Breakthrough Device Designation.
The contribution of patient associations in clinical trials
Historically, patient organizations have had the primary purpose of supporting the communities they represented. Today, this remains a crucial function, but modes have changed, as has the role that associations and patients themselves take on [...]
This article provides general information and does not constitute regulatory or legal advice. Requirements should be confirmed for the specific study, applicable regulatory framework, and markets concerned.
